Laurus Labs Q2 Results: Margins beat estimates, above 20% for the fourth straight quarter
Published on 23/10/2025 03:08 PM
Laurus Labs Q2 Results: Margins beat estimates, above 20% for the fourth straight quarterOn Monday, brokerage firm B&K Securities had initiated coverage on Laurus Labs with a "buy" rating and a price target of ₹1,030. The firm said that Laurus Labs is entering a strong growth cycle led by its high-margin CDMO business, which has gradually emerged as the company's key earnings driver.By Hormaz Fatakia October 23, 2025, 3:08:46 PM IST (Published)2 Min ReadChoose CNBC TV18 on Google
.gglsvg{margin: 5px 0 0;}
.articleWrap a.gglbtn span, .narticle-data a.gglbtn span, .gglbtn span{color: #fff; opacity:1; font: 700 11px/16px Open Sans; }
.articleWrap a.gglbtn, .narticle-data a.gglbtn,.gglbtn{width: 160px; border:none; text-decoration:none; height: 34px; background: #1767FF; color: #fff; font: 700 11px/16px Open Sans; display: flex; padding:0 8px; border-radius: 4px; justify-content: space-between;align-items:center;}
Laurus Labs Ltd. reported its results for the September quarter on Thursday, October 23, which were higher than analyst expectations on most parameters.
Revenue for the quarter increased by 35.2% from the same quarter last year to ₹1,653 crore, which is higher than the CNBC-TV18 poll expectation of ₹1,553.1 crore.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 126% to ₹403 crore. A CNBC-TV18 poll had projected the figure to be ₹368.3 crore.
EBITDA margin for the quarter expanded by more than 1,000 basis points from last year to 24.4%, higher compared to the CNBC-TV18 poll projection of 23.7%. This is the fourth straight quarter that Laurus Labs has reported EBITDA margin in excess of 20%.
Net profit for the period stood at ₹195 crore, while the CNBC-TV18 poll had projected the figure to be ₹147 crore. Laurus Labs had reported a net profit of ₹20 crore in the base quarter.
On Monday, brokerage firm B&K Securities had initiated coverage on Laurus Labs with a "buy" rating and a price target of ₹1,030. The firm said that Laurus Labs is entering a strong growth cycle led by its high-margin CDMO business, which has gradually emerged as the company's key earnings driver.
Shares of Laurus Labs are trading 0.9% higher at ₹932.4. The stock trades close to its record high level of ₹944. Shares of gained 51% so far on a year-to-date basis.Continue ReadingCheck out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsLaurus LabsQ2 resultsshare market today